Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Amblyomin-X protein, Amblyomma cajennense × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Advanced Cancer 1

Interventions

pembrolizumab 893 Carboplatin 849 Paclitaxel 835 Gemcitabine 692 Cisplatin 671 Docetaxel 626 Bevacizumab 565 Nivolumab 447 Pemetrexed 434 Cyclophosphamide 418 Capecitabine 414 Fluorouracil 361 Dexamethasone 349 Rituximab 347 Oxaliplatin 304 Injections 294 atezolizumab 276 Trastuzumab 276 Cetuximab 250 Leucovorin 247 Irinotecan 232 Prednisone 229 130-nm albumin-bound paclitaxel 225 Doxorubicin 217 Ipilimumab 206 Lenalidomide 201 Fulvestrant 195 fludarabine 187 durvalumab 185 Drug Therapy 179

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03120130 2019-10-14

Amblyomin-X

União Química Farmacêutica Nacional S/A

Phase 1 Suspended

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡